Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
How can we get pharma R&D to embrace FAIR data?
Posted on January 6th, 2020 by Ani Marrs in Pharma R&D
FAIR data, which is Findable, Accessible, Interoperable and Reusable, has the power to transform the analyses enabling drug discovery and developmentâ€”yet, the pharma industry has been slow to adopt it. There are a number of reasons for this unfortunate reality, but there is a path to realizing the potential for FAIR data in pharmaceutical R&D.
In search of a data transformation
Drug developers need to be informed on every aspect of a problem in order to build the most accurate and detailed picture possible of patients, diseases and compounds. Multi-dimensional analyses can help researchers to better understand disease and assess how chemical entities behave in biological systems.
The ultimate goal is to reduce drug development times and late-stage failures, which lowers R&D costs while increasing the chances of bringing successful treatments to patients faster.
A principled approach
In pursuit of these goals, pharmaceutical companies need to move from disconnected datasets to relevant and complementary data. The FAIR Data Principles help scientists get the most out of research data. These principles are:
- Findable – Data are richly described by metadata and have a unique and persistent identifier
- Accessible – Data and corresponding metadata are understandable to humans and machines, and accessible through defined protocols
- Interoperable – Data and corresponding metadata use formal and accessible knowledge representation to guarantee reuse
- Reusable – Metadata accurately describe the provenance and usage license for the data
Making pharma FAIR
The implementation of the FAIR Principles in pharma R&D entails a long-term overhaul of how data are created and used within an organization. Itâ€™s an important transition to make, but not easy. Implementation typically demands that there is a big culture change in an organization, requiring a shift to a model of sharing and re-using data that can initially seem counterintuitive for some managers and scientists.
The path to implementation
Itâ€™s an evolving process, but there is a growing network of organizations and tools to help â€śFAIRifyâ€ť data. Current FAIR data endeavors are not the first to attempt to merge data into meaningful information, but this is the first time when ideas, expertise and technologies align.
Bear in mind that throughout the process, investing in infrastructure and people will be an absolutely critical component. Itâ€™s crucial to have buy-in from the right people, and to have the structure in place to unleash the potential of FAIR data.
To learn more about what FAIR data has to offer pharma R&D, and how it can be made a reality, read the white paper Realizing the potential of FAIR data for pharmaceutical R&D.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Senior Marketing Manager - Entellect
- To Be a Digital Pharma Player, You Need Data â€“ Reusable Data
- Treating Pharma Data as an Asset: moving from an application centric to an information-centric organization â€“ presented by Dr. Martin Romacker, Roche
- The FAIR Toolkit Helps Researchers with Data Challenges
- How Are Regulatory Agencies Reacting to the Use of Real-World Evidence?
- Partnering to identify repurposing candidates for chronic pancreatitis